Janney Montgomery Scott LLC Reduces Stock Holdings in Eli Lilly and Company $LLY

Janney Montgomery Scott LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 309,267 shares of the company’s stock after selling 12,015 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Eli Lilly and Company were worth $235,971,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. Salem Investment Counselors Inc. lifted its stake in shares of Eli Lilly and Company by 0.6% during the 2nd quarter. Salem Investment Counselors Inc. now owns 71,869 shares of the company’s stock worth $56,024,000 after acquiring an additional 426 shares during the last quarter. Wealth Alliance Advisory Group LLC grew its position in Eli Lilly and Company by 4.5% in the 2nd quarter. Wealth Alliance Advisory Group LLC now owns 4,861 shares of the company’s stock valued at $3,789,000 after acquiring an additional 211 shares during the last quarter. Finally, New Capital Management LP purchased a new stake in Eli Lilly and Company in the second quarter worth $223,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,080.92 on Tuesday. The firm has a 50 day moving average of $1,040.85 and a 200 day moving average of $863.67. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.88, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia co‑innovation AI lab — Nvidia and Lilly will commit up to $1 billion over five years to a San Francisco‑area AI drug discovery lab that will run Nvidia’s newest Vera Rubin AI chips; the partnership could speed candidate discovery, improve R&D productivity and lower time‑to‑market for future programs. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Management says orforglipron supply is ready — Lilly told investors it’s confident in pill supply ahead of expected U.S. approval, reducing a near‑term execution risk that would otherwise pressure launches and early sales. Lilly says it’s confident weight-loss pill supply ahead of U.S. approval
• Positive Sentiment: Ventyx acquisition adds inflammation program that could complement GLP‑1 franchise — Investors cheered Lilly’s deal for Ventyx (adds VTX3232 data showing inflammation benefit with GLP‑1), which could become an add‑on therapy and extend addressable market for Lilly’s weight‑loss/diabetes drugs.
• Neutral Sentiment: Aktis Oncology stake and biotech deal exposure — Lilly anchored Aktis’ IPO and holds a meaningful equity/stake that gives exposure to targeted radiopharma programs; strategic but long‑dated and dependent on clinical milestones. Aktis Oncology aims to raise up to $317.7 million in IPO
• Neutral Sentiment: Analyst/coverage pieces highlight growth case and new tech investments — Multiple outlets and analysts are reiterating Lilly’s growth story (tirzepatide momentum, pipeline upside) and noting Lilly is building advanced compute/supercomputer capacity; that supports a bullish narrative but is forward‑looking. Here’s Why Eli Lilly (LLY) is a Strong Growth Stock
• Negative Sentiment: Competition from Novo Nordisk’s Wegovy Pill — Novo’s U.S. roll‑out of an oral Wegovy competitor raises market‑share risk for Lilly’s upcoming orforglipron launch and is a clear near‑term competitive headwind priced by investors. Novo Nordisk launches Wegovy Pill in the U.S.

Analysts Set New Price Targets

A number of research analysts have recently commented on LLY shares. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Guggenheim restated a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Five research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $1,169.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.